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inter-patient variations in relative 
biological effectiveness for cranio-
spinal irradiation with protons
Kristian S. Ytre-Hauge1*, Lars fredrik fjæra1, eivind Rørvik2, tordis J. Dahle1, Jon espen Dale3, 
Sara pilskog3 & camilla H. Stokkevåg3
cranio-spinal irradiation (cSi) using protons has dosimetric advantages compared to photons and is 
expected to reduce risk of adverse effects. The proton relative biological effectiveness (RBE) varies with 
linear energy transfer (LET), tissue type and dose, but a variable RBE has not replaced the constant RBE 
of 1.1 in clinical treatment planning. We examined inter-patient variations in RBE for ten proton CSI 
patients. Variable RBE models were used to obtain RBE and RBE-weighted doses. RBE was quantified in 
terms of dose weighted organ-mean RBE (RBEd = mean RBE-weighted dose/mean physical dose) and 
effective RBE of the near maximum dose (D2%), i.e. RBED2% = D D/RBE phys2%, 2%, , where subscripts RBE and 
phys indicate that the D2% is calculated based on an RBE model and the physical dose, respectively. 
compared to the median RBEd of the patient population, differences up to 15% were observed for the 
individual RBEd values found for the thyroid, while more modest variations were seen for the heart (6%), 
lungs (2%) and brainstem (<1%). Large inter-patient variation in RBE could be correlated to large 
spread in LET and dose for these organs at risk (OARs). For OARs with small inter-patient variations, the 
results show that applying a population based RBE in treatment planning may be a step forward 
compared to using RBE of 1.1. OARs with large inter-patient RBE variations should ideally be selected 
for patient-specific biological or RBE robustness analysis if the physical doses are close to known dose 
thresholds.
Proton therapy has been established as an important radiation treatment modality for cancer, offering improved 
sparing of normal tissue compared to conventional radiation therapy with photons1. The dosimetric advantages 
of protons have already been shown for medulloblastoma patients receiving cranio-spinal irradiation (CSI)2,3, and 
early clinical outcomes suggest that similar disease control can be achieved with reduced toxicity compared to 
photon therapy4–6. Longer follow-up and more clinical data are awaited to draw firm conclusions on the clinical 
benefits of proton CSI7.
Dosimetric benefits of proton CSI include a significant dose reduction to organs anterior to the spinal column, 
including the cochlea, transverse colon, stomach, kidney, heart, and lungs8. Besides the different spatial patterns 
in physical dose deposition, protons also have an increased biological effect compared to photons, i.e. protons 
produce more damage than photons from the same physical dose. This difference is currently accounted for by a 
dose scaling factor; the relative biological effectiveness (RBE). Although contemporary clinical proton treatment 
planning is based on a constant RBE of 1.1 (RBE1.1), the proton RBE is known to vary with linear energy transfer 
(LET), tissue type and physical dose9–11. In particular, the RBE increases due to the increase in LET towards the 
end of the proton beam range. The need to investigate the RBE further and to and to provide clinical solutions 
accounting for variations in the RBE has therefore recently been emphasized by several research groups10,12,13. To 
quantify RBE variations in proton therapy, several so-called variable RBE models have been developed. These 
models are commonly based on analysis of empirical data from in vitro proton and photon irradiation of multiple 
cell lines and use the linear-quadratic model with cell inactivation as a biological endpoint to estimate the RBE14. 
Due to the spatial variations in RBE within the patient, the biologically effective dose distribution received during 
proton CSI may differ significantly from dose estimates based on the constant RBE of 1.1, especially for organs at 
risk (OARs) located distal to the target volume, where the LET, and therefore RBE, typically is high12. Although 
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the RBE is elevated, the strong decrease in physical dose beyond the proton Bragg peak leads to a significant 
potential for sparing OARs compared to photon-based CSI.
For passively scattered (PS) proton CSI treatments, Giantsoudi et al.15 studied the LET and RBE with emphasis 
on RBE-weighted doses (RBE × dose) to the brainstem using two different variable RBE models, and reported 
mean RBE estimates consistently above 1.1 in the brainstem. Further, the RBE-weighted doses to OARs in two 
CSI patients were investigated in a study of vertebral column sparing techniques by applying five different treat-
ment planning strategies16. This study showed elevated RBE for OARs distal to the spine, including the thyroid, 
lungs, esophagus and heart, and that the RBE values and doses were strongly dependent on the target volume 
delineation. The proton RBE for the target volumes of medulloblastoma patients was also assessed by Jones et 
al.17 who suggested a risk of tumor under-dosage due to indications of low RBE in medulloblastoma tumor cells 
compared to surrounding tissues. The same study also emphasizes the risks from elevated RBE in brain tissues.
While previous studies have investigated inter-patient variations in RBE for several other indications18–21, 
the RBE variations in standardized CSI proton treatments have so far received little attention. For CSI using 
intensity modulated proton therapy (IMPT), the variations in RBE in OARs across different patients and RBE 
models remains unexplored, and may differ from those found for PS protons22. The objective of our study was 
therefore to investigate inter-patient variations in RBE for patients receiving CSI with IMPT, assessing also the 
impact of uncertainties in tissue parameters and differences between RBE models. Two variable RBE models, 
based on a broad range of in vitro experiments, were applied to calculate the RBE and RBE-weighted dose for 
ten CSI patients. The (α/β)x (fractionation sensitivity of photon-based radiotherapy), LET and (physical) dose 
were used as model input parameters. The LET and dose were obtained through Monte Carlo simulations on a 
voxel-by-voxel basis for each patient and treatment plan.
Results
Dose and dose-averaged LET (LETd) distributions for one patient are shown in Fig. 1. The lungs, heart and thyroid 
are partially exposed to moderate doses and relatively high LETd values. Compared to the RBE1.1 doses (Fig. 1a,c) 
the RBE-weighted doses from the variable RBE model by Rørvik et al. (ROR)9 (Fig. 1b,e) are slightly elevated, 
indicating RBE above 1.1. A clear increase in LETd can be seen along the beam direction (Fig. 1c,f). Further com-
parison to a photon therapy treatment plan for this patient can be found in Fig. 1S and 2S in the Supplementary 
Materials.
Dose volume histograms (DVHs) using RBE1.1 and LET volume histograms (LVHs) for the OARs are shown in 
Fig. 2, illustrating the degree of inter-patient variations for different OARs in physical dose and LETd which both 
affects the RBE. Dose, LETd, and RBE metrics are reported in Table 1 for all OARs and RBE models. The great-
est variation in dose between patients was seen for the thyroid, with mean doses in the range 1.2–8.4 Gy(RBE) 
for RBE1.1 which increased to 1.7–10.5 Gy(RBE) using the variable RBE model by McNamara et al.23 (MCN). 
Variations in LETd across the patients were greatest for the thyroid and heart. The inter-patient variations in near 
maximum dose (D2%) were also largest for the thyroid and heart, and again, the variable RBE models gave higher 
doses compared to RBE1.1.
Figure 3 shows the calculated dose-weighted organ-mean RBE values (RBEd) and effective near maximum 
dose RBE (RBED2%) for all patients and OARs, as well as the median RBEd and median RBED2% across the patient 
b)a) c)
e)d) f)
Figure 1. Dose distributions obtained with RBE1.1 (a,d) and the variable RBE model ROR ((α/β)x of 3.0 Gy) 
(b,e), and the corresponding LETd distribution (c,f). Dose and LETd values in voxels receiving less than 
0.5 Gy(RBE) are set transparent. The spinal planning target volume, lungs, heart and thyroid are outlined in red, 
blue, yellow and blue, respectively.
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population for each RBE model, calculated from the ten individual RBEd and RBED2% values, respectively. The 
inter-patient variations in RBEd and RBED2%, follow the same trends: Large inter-patient RBE variations were 
observed for the thyroid, followed by moderate variations for the heart and lungs, whereas only minor variations 
were seen for the brainstem, with maximum deviation from the median RBEd and RBED2% of 0.5% and 1.5%, 
respectively. In comparison, the difference in brainstem RBEd between the ROR and MCN models was between 
2.8% and 3.0% for all patients, with the MCN model resulting in the highest values. In general, the ROR and MCN 
models predicted similar RBE values across the patient population, but with slightly higher values for the MCN 
model. The maximum absolute difference in RBEd and RBED2% between the models was 0.07 and 0.09, respec-
tively. For the heart and lungs, slightly lower RBED2% values were observed compared to the RBEd, while no con-
sistent differences between RBED2% and RBEd were observed for the thyroid and brainstem.
The RBE variations were largest in the organs with inhomogeneous dose distributions, and the inter-patient 
variations in RBEd for the thyroid (up to 15%) may be attributed to the wide range in dose and in LET between 
patients (Fig. 2d,h). The variations in RBE within the (α/β)x confidence intervals (CI) were larger than both 
inter-patient variations and model differences, with the lowest (α/β)x values resulting in the highest RBE, as 
expected.
The population median RBEd values for the MCN model were 1.62 (heart), 1.18 (brainstem), 1.27 (lungs) and 
1.44 (thyroid). These values differ significantly from the clinically applied RBE of 1.1, but are only slightly differ-
ent from most individual RBEd values across the ten patients, as can be seen by comparing the data points and 
dashed lines in Fig. 3a. The clinical impact of the RBE variations are, however, dependent on the physical dose 
levels which varies strongly between the OARs. The resulting inter-patient variations in RBE-weighted doses and 
Figure 2. The upper panels show DVHs for the heart (a), brainstem (b), lungs (c) and thyroid (d) for all ten 
patients calculated with RBE1.1. The lower panels show LVHs for the heart (e), brainstem (f), lungs (g) and 




(Range) [keV/µm] RBE model








RBE1.1 0.7 (0.4–1.7) 8.5 (6.0–16.0) — —
Heart 13.0 (9.6–15.0) MCN3.0Gy 0.9 (0.6–2.4) 11.6 (8.5–20.3) 1.62 (1.53–1.65) 1.51 (1.40–1.56)
ROR3.0Gy 0.9 (0.6–2.3) 11.2 (8.2–19.6) 1.56 (1.47–1.59) 1.46 (1.35–1.51)
RBE1.1 54.3 (52.8–54.6) 55.4 (55.1–55.6) — —
Brainstem 1.8 (1.8–1.9) (CSI) MCN2.1Gy 58.1 (56.8–58.5) 59.8 (59.3–60.4) 1.18 (1.17–1.18) 1.18 (1.18–1.20)
2.2 (2.1–2.3) 
(boost) ROR2.1Gy 56.5 (55.2–56.8) 57.9 (57.5–58.3) 1.14 (1.14–1.15) 1.15 (1.14–1.16)
RBE1.1 4.0 (2.2–4.8) 20.4 (17.6–21.4) — —
Lungs 4.8 (3.9–5.2) MCN4.0Gy 4.7 (2.5–5.6) 22.6 (19.6–23.6) 1.27 (1.24–1.29) 1.22 (1.20–1.23)
ROR4.0Gy 4.6 (2.4–5.5) 22.1 (19.2–23.1) 1.25 (1.23–1.27) 1.20 (1.18–1.20)
RBE1.1 3.9 (1.2–8.4) 14.0 (6.2–18.7) — —
Thyroid 4.5 (4.1–6.1) MCN3.0Gy 5.2 (1.7–10.5) 17.6 (9.4–22.2) 1.44 (1.36–1.67) 1.40 (1.31–1.66)
ROR3.0Gy 5.1 (1.7–10.3) 17.1 (9.0–21.6) 1.42 (1.34–1.61) 1.36 (1.27–1.58)
Table 1. Dose, RBE and LETd metrics reported as median and range over the patient group for the different 
RBE models and OARs. Results for the variable RBE models are reported for the nominal (α/β)x values, 
indicated by subscripts in the table.
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how these differ from doses based on RBE1.1 are illustrated in Fig. 4. The figure shows RBE-weighted doses calcu-
lated for each of the ten patients using both their individual RBE (data points in Fig. 3a) and the population 
median RBEd (dashed lines from Fig. 3a), together with RBE-weighted doses calculated with RBE1.1. The variable 
RBE doses are calculated using the MCN model with nominal (α/β)x values, and the largest inter patient variation 
in RBE-weighted dose are again seen for the thyroid. However, we can also see that the largest deviations in 
RBE-weighted dose compared to RBE of 1.1 are present for the brainstem, mainly due to the high physical dose 
here. Overall, it is clear that the population based dose estimates are much closer to the individually calculated 
RBE-weighted doses as compared to the RBE1.1 doses. This is particularly evident for the brainstem. The largest 
deviation from the population median RBEd was 0.22 (thyroid of patient number 8). The mean dose to the thyroid 
for this patient (calculated with RBE1.1) was, however, only 1.24 Gy(RBE). The difference in RBE-weighted dose 
calculated from the population median RBE and the patient specific RBE was therefore only 0.25 Gy(RBE). 
However, for the RBED2%, the corresponding difference was 1.46 Gy(RBE). For most cases, the difference in 
RBE-weighted dose calculated with the individual and median RBE was negligible, with maximum differences (in 
Gy(RBE)) of 0.14 (heart), 0.22 (brainstem), 0.11 (lungs), 0.65 (thyroid). Similar results were also seen for the ROR 
model.
Discussion and conclusion
Overall, the largest inter-patient variations in organ specific RBE were observed for the thyroid, while modest 
variations were observed for the heart and lungs. Only small variations were seen for the brainstem. The observed 
RBE variations within the patient population were similar for the organ mean dose-weighted RBE (RBEd) and the 
effective near maximum dose RBE (RBED2%). The two variable RBE models applied showed good agreement, with 
estimates of RBE consistently above 1.1. The results for the brainstem show that RBE variations among patients 
can be very small for a standardized treatment using the same beam configurations. In such cases applying a 
population based RBE value may be a step forward in treatment planning compared to using RBE of 1.1, as illus-
trated by the results in Fig. 4. These results also emphasize that the impact of inter-patient RBE variations must be 
evaluated in light of the physical organ doses, which in this study varied from mostly very low doses to the heart 
to high doses for the brainstem.
The observed inter-patient variations in RBE for the thyroid can be attributed to the spread in LET and dose 
between patients (Fig. 2d,h). The location of the thyroid distal to the spinal PTV can lead to significant doses 
deposited here, depending on the anatomy of the patient, i.e. the proximity of the thyroid to the target volumes. 
The margins applied to ensure dose coverage of the spinal PTV may also affect the dose and LET to the thyroid. 
The results presented in Fig. 4d, show that inter-patient variations in RBE does not necessarily lead to large dif-
ferences between the RBE-weighted dose estimates based on the individual and population based RBE. In this 
particular case, the relatively low physical dose to the thyroid makes the RBE variations less critical.
The heart is also located distal to the PTV, but compared to the thyroid, the doses to the heart are low, and only 
a small fraction of the heart typically receives doses above 3–4 Gy(RBE). Therefore, the RBED2% parameter is of 
more relevance for the heart than the RBEd parameter. Although some inter-patient variation in RBED2% was 
observed, the population median RBED2% values (Fig. 3b) give a reasonable representation of the RBED2% for each 
patient. The RBEd and RBED2% parameters gave estimates of similar magnitude for the heart, due to the 
dose-weighting included in the RBEd parameter. This demonstrates the robustness of this parameter compared to 
using the arithmetic mean of RBE values in all voxels. In principle, the OAR mean RBE could be calculated by 
simply averaging over RBE values on a voxel-by-voxel basis in the OAR of interest. However, for the purpose of 
evaluating RBE in a clinical setting, this approach could lead to artificially high RBE values in cases where the 
dose is inhomogeneous and low in parts of the organ. The low dose regions would then contribute to a significant 
increase in mean or median RBE as the RBE, for most models, is inversely proportional with dose14, and in addi-
tion, low dose regions often have high LETd due to low energy scattered or secondary ions or neutrons. 
Considering the dose and LETd distributions for the heart (Fig. 1) it is probable that the very high LETd values 
Figure 3. Mean dose-weighted RBE (a) and effective near maximum dose RBE (b) for the heart, brainstem, 
lungs and thyroid in the ten patients. The markers show the RBE values for individual patients, while the dashed 
lines represent the median over the patient group. The shaded region represents the possible RBE values for the 
MCN model within the (α/β)x confidence intervals for the different OARs.
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observed in the LVH (Fig. 2e) originate from regions with negligible doses, mainly from secondary particles distal 
to the primary beam. Yet, LETd values above 10 keV/µm were observed for the heart in regions receiving doses 
above the threshold of 0.5 Gy(RBE) illustrated in Fig. 1c. Overall, the RBEd and RBED2% parameters gave similar 
values for all OARs. The slightly lower RBED2% observed for the heart and lungs could be due to lower LET in the 
high dose region (contributing more to RBED2% than RBEd), or due to the inverse dependence of RBE on dose, 
which in general gives a higher RBE in the low dose regions.
The inter-patient variations observed for the lungs were modest, resulting in only small deviations from the 
population median values (Fig. 3), and the agreement between RBE-weighted lung doses from individual and 
population RBE (Fig. 4c) was good for all patients. The dose deposition in the lungs is a result of lateral and distal 
margins as well as laterally scattered radiation and secondary particles, indicating the effect of anatomical differ-
ences. This leads to intermediate LETd values and doses compared to the extremes seen for the heart (low dose, 
high LETd) and brainstem (high dose, low LETd).
The mean doses to the brainstem were similar for all patients (53–55 Gy(RBE1.1)), in combination with a rela-
tively low LETd. These two factors contribute to low RBE values, and also relatively small variations in the brain-
stem RBE. However, contrary to the observations for the thyroid, the high doses deposited in the brainstem 
implies that even small changes in the RBE still could lead to non-negligible changes in RBE-weighted dose; the 
highest median RBE across the patient population (1.18 for both RBEd and RBED2%), resulted in an increase in 
estimated RBE-weighted mean dose of almost 4 Gy(RBE). The small degree of inter-patient RBE variations 
observed for the brainstem, in combination with consistent elevated RBE across the patient population, shows 
that the use of individual or population based RBE for the brainstem in CSI treatment planning may be advanta-
geous compared to using the conventional RBE of 1.1. A recent review of brainstem injury from protons empha-
sizes the uncertainty in the proton RBE and the potential impact this may have on brainstem injury24. Brainstem 
injury incident rates are relatively low, and a clear connection between elevated RBE and brainstem injury has not 
yet been shown. However, across different institutions and treatment modalities (photons and protons) patients 
with brainstem necrosis received higher doses (median dose 54.7 Gy(RBE)) compared to those without brainstem 
injury (median dose 51.7 Gy(RBE)). With doses close to the clinical constraints reported by Haas-Kogan et al.24 
(D50% < 54 Gy(RBE), D0.1cc < 58 Gy(RBE) and D10% < 56 Gy(RBE)), the increase in RBE-weighted dose when mov-
ing to variable RBE (as seen in Table 1) illustrates that RBE effects could have a negative clinical impact for these 
patients.
Figure 4. Comparison of RBE-weighted mean doses for the heart (a), brainstem (b), lungs (c) and thyroid (d) 
calculated from the population median RBE (blue), the patient specific (individual) RBE (green) and RBE1.1 
(black). RBE estimates are based on the MCN model and nominal (α/β)x values.
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The brainstem RBE values were similar to previously published results15; for 16 patients Giantsoudi et.al. 
found RBE values of 1.11–1.17 using the Frese model and 1.19–1.31 for the Carabe model. For the mean LETd 
they found values in the range 2.5–3.9 keV/µm for the brainstem, which is somewhat higher compared to our 
study. It should, however, be noted that this study was performed using passively scattered proton therapy, which 
can result in different LET and RBE distributions compared to IMPT22. In addition, the brainstem LETd can be 
dependent on other factors including field arrangements and target definitions25.
A previous study of two pediatric CSI patients (8 and 11 years) reports average RBE values (using MCN(α/β)x 
3Gy) of 1.83 (heart), 1.58 (lungs) and 1.98 (thyroid)16. Using the same RBE model, our corresponding population 
median values for the heart (1.62) and lungs (1.27) were slightly lower. For the thyroid we observed a lower RBE 
of 1.44. Differences in RBE may be related to the obtained average (mean) dose of 1.5 Gy(RBE1.1) for the two 
patients compared to the median (mean) dose of 3.9 Gy(RBE1.1) across our patient population, again depending 
on patient anatomy, i.e. age/size of patient. Due to the small number of patients in the cited study, it is difficult to 
evaluate if the observed differences are due to inter-institution differences or inter-patient variations. The cited 
study also illustrated how different target definitions can affect the doses to OARs including the lungs, heart and 
thyroid. Traditionally, the whole vertebral column is included in the target volume for pediatric CSI patients to 
avoid the risk of spinal deformity related to an asymmetric dose across the vertebral body. This comes at the cost 
of increased doses to the OARs distal to the spinal target volume, and vertebral column sparing techniques are 
therefore an interesting option which potentially could lead to a clinical benefit for this patient group.
The tissue dependence of RBE for protons is included in most recent phenomenological RBE models. 
However, these parameters are associated with uncertainties both for the target regions as well as OARs. For the 
lungs, we adopted the (α/β)x value of 4.0 Gy used by Öden et al.20 and based on the study by Bentzen et al.26. 
Radiation pneumonitis was the biological endpoint for these values, while e.g. late phase fibrosis (α/β)x was sug-
gested to be in the range of 2.0–3.0 Gy, also within the confidence intervals (CI) included in the present study. The 
brainstem (α/β)x value is normally considered to be in the order of 2.0 Gy, although uncertainties are present also 
here27. For the heart and thyroid, a generic value for late effects of 3.0 Gy was applied28. Depending on the (α/β)x, 
the median RBEd for the brainstem ranged from 1.15 to 1.22. Corresponding ranges for the heart and thyroid 
were 1.44–1.99 and 1.32–1.72. The uncertainties in the (α/β)x values should therefore be carefully assessed both 
when evaluating the RBE values presented here and when estimating normal tissue complication probability for 
specific endpoints. The RBE changes monotonously with (α/β)x for the ROR and MCN models14. The RBE for all 
(α/β)x values within the confidence intervals will therefore fall within the shaded regions in Fig. 3. Thus, the RBE 
from other (α/β)x values can be roughly assessed from the figures, and in principle, the variations in RBE with 
(α/β)x could be determined analytically without new simulations.
While Wedenberg et al.29 showed that the (α/β)x could be correlated to the RBE it is not clear if combining 
the α and β parameters into a single parameter is the best approach. Tissue parameters could also be handled 
separately, as in the proton RBE model by Jones et al.30. In radiosensitive tissue such as the brainstem and other 
parts of the central nervous tissue with low (α/β)x the β parameter becomes increasingly important. RBE models 
differ significantly in how the RBEmin parameter (√β/βx) is implemented. While many models (including the ROR 
model) define the RBEmin as a constant of 1, there are RBE models with RBEmin both increasing30,31 and decreasing 
(including the MCN model) with LET. A recent study shows that the choice of dose range in the experimental in 
vitro data for the models may lead to different conclusions regarding the LET dependence of RBEmin, and that data 
sets including low doses (below 1 Gy) indicate a slight increase in RBEmin with LET32. Overall, further investiga-
tions of the tissue dependency of the proton RBE are needed as the uncertainties in RBE associated with different 
tissues remains a significant challenge, complicating the introduction of variable RBE models in the clinical rou-
tine. Furthermore, when comparing different proton RBE models, derived from different experimental data, it is 
also clear that other uncertainties than the tissue dependence are present. Compared to other proton RBE models, 
the two models applied in this work showed intermediate RBE values14. One of the reasons for this may be that 
both the chosen models are based on large datasets from a number of different in vitro experiment, as opposed to 
many other proton RBE models.
Overall, this study demonstrates that for proton CSI treatments, OARs are subject to different degrees of 
inter-patient RBE variations. The observed RBE variations were reflected by the heterogeneity in dose and LET 
across the patients. Further RBE variations due to difference in radiosensitivity between patients (e.g. due to age) 
can, however, not be excluded. We also showed that the population based RBE values differ significantly from the 
clinically used value of 1.1. For OARs with small inter-patient variations in RBE, applying a population based RBE 
in treatment planning may therefore be a step forward compared to using an RBE of 1.1. Nevertheless, applying 
a constant RBE, although different from 1.1, has some of the same limitations as the current clinical practice as 
it ignores the variability in RBE within the organ. It should therefore be carefully evaluated if this approach gives 
disadvantages or advantages over other techniques accounting for a variable RBE such as LET-based optimiza-
tion33,34. One limitation of purely LET-based optimization, compared to the population based approach presented 
here, is that it ignores the large variability in RBE with tissue type. Generally, OARs with large inter-patient RBE 
variations should be selected for patient-specific biological or RBE robustness analysis if the physical doses are 
close to known dose thresholds. Although proton CSI is a relatively standardized treatment with similar field and 
target configuration across different institutions, the variations in dose, LET and RBE across institutions could 
differ e.g. if alternative target definitions are used, and inter-institution differences should therefore be investi-
gated further.
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Methods
IMPT plans for ten children (5–11 years) were generated using Eclipse (Varian Medical Systems, Palo Alto, CA, 
USA) applying RBE1.1 in the optimization. The planning target volume (PTV) included the cranio-spinal axis 
with vertebral bodies prescribed 23.4 Gy(RBE1.1) and a posterior fossa boost up to 54 Gy(RBE). Fraction doses 
were 1.8 Gy(RBE) for both the CSI and boost plans. Two posterior fields were applied to cover the spinal target 
volume while two lateral oblique opposing fields were applied the cranial target volume. Two additional lateral 
oblique opposing fields were applied to cover the boost volume. Optimization of the treatment plans was adapted 
from the standardized CSI treatment planning approach (including field angles and treatment planning margins) 
as described by Giebeler et al.35.
The plans were recalculated with the FLUKA Monte Carlo code36,37, obtaining the physical dose and LETd on 
a voxel by voxel basis, as described in Fjæra et al.25. LET values were calculated based on primary and secondary 
protons. To estimate the RBE and RBE-weighted dose to the patients, two proton RBE-models were coupled to 
the Monte Carlo simulations. RBE was calculated based on the fraction doses. The models by McNamara et al. 
(MCN)23 and Rørvik et al. (ROR)9 include the LET, dose and (α/β)x (fractionation sensitivity of photon treat-
ments) as input parameters. The RBE was calculated using organ specific (α/β)x values. For the heart, brainstem, 
lungs and thyroid, we applied (α/β)x values of 3 (1.5–4.5) Gy28, 2.1 (1.1–3.2) Gy38,39, 4.0 (2.0–6.0)20,26 Gy and 3 
(1.5–4.5) Gy28, respectively. Values in parenthesis are estimated 95% confidence intervals (CI) used to determine 
the impact of the tissue parameters and their uncertainty. The MCN model assume a linear relationship between 
LET and RBE and can therefore make use of the LETd as input parameter while the ROR model is based on a 
non-linear LET-RBE relationship and requires the full LET spectrum to estimate the RBE.
Dose and LETd volume histograms (DVH/LVH), RBE and mean and near maximum (D2%) values of 
RBE-weighted doses were estimated for important OARs: the heart, brainstem, lungs and thyroid. The D2% 
parameter represent maximum dose received by 2% of the volume. From the RBE distribution and dose maps, the 



























where N is the total number of voxels in the organ and Dphys,i and RBEi are the physical dose and RBE in voxel 
i. Equation (1) simplifies to the ratio of organ-mean RBE-weighted dose over organ-mean physical dose. This 
approach was chosen instead of calculating the arithmetic mean RBE on a voxel-by-voxel basis as the latter 
method will lead to less clinically relevant RBE values due to the high RBE in regions of negligible dose. In order 
to also evaluate the increase in D2% from RBE effects a different approach must be used. In principle, the maxi-
mum RBE-weighted dose can be located in different voxels depending on whether a variable RBE model or RBE1.1 
is used. In clinical evaluation of the treatment plans, the D2% parameter is normally used without considering the 
location of the near maximum dose. In this study we therefore defined the effective maximum dose RBE (RBED2%) 
as the ratio of D2% for an RBE model and D2% for the physical dose. There was no requirement of spatial corre-












where D2%,RBE is the near maximum RBE-weighted dose while D2%phys is the near maximum physical dose. The 
RBED2% can then be used together with the physical dose to determine the increase in near maximum dose for a 
certain organ due to RBE effects.
From the RBEd and RBED2% values, the population median RBE values were retrieved. In addition to the con-
ventional RBE-weighted doses calculated with the patients individual RBE, the population median RBE values 
were applied to calculate RBE-weighted doses for all OARs and patients. To explore the usefulness of the popula-
tion median RBE values, i.e. how well these values represent the RBE for individual patients, the population based 
RBE-weighted doses were compared to RBE-weighted doses calculated using the individual RBE values as well as 
doses calculated with RBE1.1. The population based RBE-weighted doses were calculated as:
= ×D D RBE , (3)RBE phys d median,
where and Dphys is the mean dose for a specific OAR and patient, and RBEd median,  is the median RBEd across the 
ten patients for this specific OAR.
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